Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes

Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes Anna L. Coleman-Hulbert, Erik Johnson, Christine A. Sedore, Stephen A. Banse, Max Guo, Monica Driscoll, Gordon J. Lithgow, and Patrick C. Phillips 1. Institute of Ecology and Evolution, University of Oregon, Eugene, Oregon 97403, USA 2. Division of Aging Biology, National Institute on Aging, Bethesda, Maryland 20892, USA 3. Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08854, USA 4. The Buck Institute for Research on Aging, Novato, California 94945, USA *Contributed equally to this work §Correspondence to: Patrick C. Phillips (pphil@uoregon.edu)


Description
The Caenorhabditis Intervention Testing Program (CITP) is a National Institutes of Aging (NIA)-funded multi-institutional research consortium that investigates chemical interventions for their potential to extend lifespan and healthspan across a genetically diverse panel of Caenorhabditis nematodes (Lucanic et al., 2017a). To date, the CITP has tested more than 20 compounds, including many of those previously surveyed in mice by the NIA-funded Interventions Testing Program (ITP) (Miller et al., 2007;Nadon et al., 2008). With compounds tested across multiple strains, species, labs, and concentrations, the CITP produces a large body of work before a compound traverses the full testing workflow. The intensive effort required poses an important challenge for the CITP as to how to systematically identify and prioritize compounds to test. Indeed, the selection of chemical interventions that might hold the greatest potential for efficacy is a challenge to the aging field in general.
One approach to chemical intervention prioritization is to use computational approaches that rank candidate compounds based on their likelihood to confer longevity benefits. For example, Ziehm et al. (2017) developed a ranking algorithm that combined information on genetic effects on aging, drug-target orthology relationships and sequence conservation, 3D protein structures, drug binding, and bioavailability. Here, we present the results of a test for lifespan effects of imatinib mesylate (a tyrosine kinase inhibitor; commercially known as Gleevec). Imatinib mesylate was the highest scoring drug-like compound with known mammalian targets ranked for likelihood to modulate aging in the invertebrates C. elegans and D. melanogaster (Ziehm et al., 2017). Imatinib was also highly ranked by a separate computational approach that predicted compound interventions for human aging (Fuentealba et al., 2019).
We assayed lifespan in response to imatinib mesylate exposure in three Caenorhabditis species in triplicate using our previously published workflow (Lucanic et al. 2017a;. In brief, imatinib mesylate (Toronto Research Chemicals) was dissolved in water and diluted appropriately such that 125 µl of solution could be added to 35 mm diameter NGM plates containing 51 µm FUdR in order to generate the following final imatinib mesylate concentrations: 0.01 µM, 0.1 µM, 1.0 µM, 10 µM, 50 µM, 100 µM, 500 µM, and 1 mM. Worms were age-synchronized by timed egg-lays on standard NGM plates, then transferred at a density of 50 animals per 35 mm plate (control or imatinib mesylate) in triplicate when they reached adulthood. Animals were maintained at 20 °C and moved to fresh experimental plates on the first, second, and fifth day of adulthood, then once weekly afterward, and fed on OP50-1 lawns for the duration of the experiments. Thrice weekly, we observed animals for spontaneous movement or movement after gentle perturbation with a 0.2 mm diameter platinum wire. Death was scored as a lack of movement.
Our results indicate that imatinib mesylate does not extend lifespan in any of the Caenorhabditis species at the concentrations tested here; in fact, at some concentrations, this compound reduced nematode lifespan, although this effect was not consistent among species (Fig. 1). However, as there was only a single biological replicate, this conclusion should be considered as preliminary. Interventions may be ineffective due to a range of causes including permeability barriers, compound stability in vivo, and metabolism by the bacterial food source. While we did not observe any lifespan-extending properties of imatinib mesylate in this study, it is important to note that the ranking methodology used to prioritize imatinib mesylate (Ziehm et al., 2017) predicts whether compounds have aging-modulating effects rather than lifespan-extending properties per se. Notably, Ziehm et al. (2017) identified two aging-associated likely targets of imatinib, ABL1 and MAPK14. In C. elegans, pmk-1 (MAPK14 ortholog) deletion mutants exhibit decreased survival compared to wild-type (Park et al., 2018) indicating that inhibition by imatinib mesylate could likewise result in decreased lifespan. In contrast, abl-1 (ABL1 ortholog) mutants are resistant to endoplasmic reticulum stress induced by tunicamycin (Judy et al., 2013). Imatinib mesylate may target abl-1 as it phenocopies abl-1 mutants with respect to cell death phenotypes (Deng et al., 2004).
In future studies, it will be important to further characterize whether compounds highly ranked in methodologies, such as the one discussed here, possess health or longevity-promoting effects as well as putative aging-modulating effects.